Drug-induced liver disease

Current Opinion in Gastroenterology

Volumn 19, Issue 3, 2003, Pages 203-215

  Novak, David ^a   Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ANTIRHEUMATIC AGENT; BROMFENAC; CARBAMAZEPINE; ENTACAPONE; GATIFLOXACIN; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ISONIAZID; LAMOTRIGINE; LEFLUNOMIDE; METHOTREXATE; MEVINOLIN; MIRTAZAPINE; NEFAZODONE; PARACETAMOL; PIOGLITAZONE; PRAVASTATIN; PSYCHOTROPIC AGENT; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TICLOPIDINE; TROGLITAZONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; CHOLESTASIS; CHRONIC HEPATITIS; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG USE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; RASH; REVIEW; RISK FACTOR;

EID: 0037405482     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200305000-00004     Document Type: Review

References (113)

1. Kaplowitz N, DeLeve LD: Drug Induced Liver Disease. New York: Marcel Dekker, 2003. A new textbook on DILD, emphasizing mechanisms of injury with clinical overviews for all major drug classes.
2. Farrell GC, Liddle C: Drugs and the liver updated, 2002. Semin Liver Dis 2002, 22:109-113. An excellent summary of many aspects of DILD, including causality assessment.
3. Nierenberg DW: Did this drug cause my patient's hepatitis? And related questions. Ann Intern Med 2002, 136:480-483.
4. Andrade RJ, Lucena MI, Fernandez MC, et al.: Cholestatic hepatitis related to use of irbesartan: a case report and literature review of angiotensin II antagonist-associated hepatotoxicity. Eur J Gastroenterol Hepatol 2002, 14:887-890.
5. Zapater P, Reus S, Tello A, et al.: A prospective study of the clarithromycin-digoxin interaction in elderly patients. J Antimicrob Chemother 2002, 50:601-606.
6. Peire MA, Lucena MI, Ruiz-Extremera, et al.: Drug-induced hepatotoxicity in children. Where we are and where are we going. An Esp Pediatr 2002, 56:434-442.
7. Sgro C, Clinard F, Ouazir K, et al.: Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36:451-455. Demonstrates that causality assessment can be effectively used by all practitioners. The annual incidence rate of DILD was 16 times greater than the rate based on spontaneous reports.
8. Clarkson A, Choonara I: Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child 2002, 87:462-466.
9. Ostapowicz G, Fontana RJ, Schiodt Fu, et al.: Results of a prospective study of acute liver failure at 17 tertiary care centers in the US. Ann Intern Med 2002, 137:947-954. Acetaminophen remains the most common cause of acute liver failure in the United States (39o/o of cases), with other drugs accounting for another 13%. Overall, DILD was responsible for more than half of all cases of acute liver failure.
10. Prati D, Taloll E, Zanella A, et al.: Updated definitions of healthy ranges of serum alanine aminotransferase levels. Ann Intern Med. 2002, 137:1-9. Retrospective, cohort study that questions the current upper limits of normal for ALT, suggesting that "normal" values for men and women should be lowered to 30 U/L and 19 U/L, respectively.
11. Kuffner EK, Dart RC, Bogdan GM, Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001, 161:2247-2252.
12. Holtzman JL: The effect of alcohol on acetaminophen hepatotoxicity [letter]. Arch Intern Med 2002, 162:1193.
13. Soll AH: Is acetaminophen really safe in alcoholic patients [letter]? Arch Intern Med 2002, 162:1194.
14. Oveido J, Wolfe MM: Alcohol, acetaminophen, and toxic effects on the liver. Ann Intern Med 2002, 162:1194-1195.
15. FDA announces new alcohol warnings for pain relievers and fever reducers [FDA press release]. Available at: http://www.fda.gov/bbs/topics/NEWS/NEW00659.html. Accessed February 12, 2003.
16. Schmidt LE, Dalhoff K, Poulsen HE: Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002, 35:876-882. Acute alcohol ingestion protected against APAP toxicity in chronic alcoholics but not in nonalcoholics.
17. Schiodt FV, Lee WM, Bondesen S, et al.: Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen over dose. Aliment Pharmacol Ther 2002, 16:707-715. Acute alcohol intake was not significantly associated with course and outcome of acute APAP overdose.
18. Bolesta S, Haber SL: Hepatotoxicity associated with chronic acetaminophen administration in patients without risk factors. Ann Pharmacother 2002, 36:331-333.
19. Riordan SM, Williams R: Alcohol exposure and paracetamol-induced hepatotoxicity. Addict Biol 2002, 7:191-206.
20. Zhao P, Slattery JT: Effects of ethanol dose and ethanol withdrawal on rat liver mitochondrial glutathione: implication of potentiated acetaminophen toxicity in alcoholics. Drug Metab Dispos 2002, 30:1413-1417.
21. Schiodt FV, Ott P, Christensen E, et al.: The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage. Clin Pharmacol Ther 2002, 71:221-225.
22. Schmidt LE, Dalhoff K: Serum phosphatase is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 2002, 36:659-665.
23. Bernal W, Donaldson N, Wyncoll D, et al.: Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002, 359:558-563.
24. Schiodt FV, Rochling FA, Casey DL, et al.: Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997, 337:1112-1117.
25. Gyamlani GO, Parikh OR: Acetaminophen toxicity: suicidal vs. accidental. Crit Care 2002, 6:155-159.
26. Rumack BH: Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002, 40:3-20.
27. Buckley NA, Srinivasan J: Should a lower treatment line be used when treating paracetamol poisoning in patients with chronic alcoholism? A case for. Drug Saf 2002, 25:619-624.
28. Dargan PI, Jones AL: Should a lower treatment line be used when treating paracetamol poisoning in patients with chronic alcoholism? A case against. Drug Saf 2002, 25:625-632.
29. Fiorucci S, Antonelli E, Mencarelli A: A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway. Br J Pharmacol 2002, 135:589-599.
30. Gardner CR, Laskin JD, Dambach DM, et al.: Reduced hepatotoxicity of acetaminophen in mice lacking inducible nitric oxide synthase: potential role of tumor necrosis factor-alpha and interlukin-10. Toxicol Appl Pharmacol 2002, 184:27-36.
31. Hoegberg LC, Angelo HR, Christophersen AB, et al.: Effect of ethanol and pH on the adsorption of acetaminophen to high surface activated charcoal, in vitro studies. J Toxicol Clin Toxicol 2002, 40:59-67.
32. Ash SR, Caldwell CA, Singer GG et al.: Treatment of acetaminophen-induced hepatitis and fulminant hepatic failure with extracorporeal sorbent-based devices. Adv Ren Ther 2002, 9:42-53.
33. Coleman CI, Spencer JV, Chung JO, et al.: Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 2002, 36:1162-1167.
34. Lewis JH: Drug-induced liver disease. Curr Opin Gastroenterol 2002, 18:307-313.
35. Bataille L, Rahier J, Geubel A: Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease. J Hepatol 2002, 37:696-699.
36. Hui CK, Yuen MF, Wong WM, et al.: Mirtazapine-induced hepatotoxicity. J Clin Gastroenterol 2002, 35: 270-271.
37. Tirmentstein MA, Hu CX, Gales TL, et al.: Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol Sci 2002, 69:131-138.
38. Yamamoto Y, Yamazaki H, Ikeda T, et al.: Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab Dispos 2002, 30:155-160.
39. Stumvoll M, Haring HU: Glitazones: clinical effects and molecular mechanisms. Ann Med 2002, 34:217-224.
40. Lebovitz HE: Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002, 18(suppl 2):S23-S29.
41. Lebovitz HE, Kreider M, Freed MI: Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002, 25:815-821.
42. Lloyd S, Hayden MJ, Sakai Y et al.: Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chem Biol Interact 2002, 142:57-71.
43. Li J, Kaneko T, Wang Y et al.: Troglitazone enhances the hepatotoxicity of acetaminophen by inducing CYAP3A in rats. Toxicology 2002, 176:91-100.
44. El-Serag HB, Everhart JE: Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002, 122:1822-1828. The risk of acute liver failure in diabetics was significantly higher than among non-diabetics, even after excluding patients with chronic liver disease, viral hepatitis, or those taking troglitazone.
45. May LD, Lefkowitch JH, Kram MT: Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 2002, 136:449-452.
46. Pinto AG, Cummings OW, Chalasani N: Severe but reversible cholestatic liver injury after pioglitazone therapy [letter]. Ann Intern Med 2002, 137:857.
47. Bonkovsky HL, Azar R, Bird S, et al.: Severe cholestatic hepatitis caused by thiazolidinediones. Dig Dis Sci, 47:1632-1637.
48. van Outryve S, Schrijvers D, van den Brande, et al.: Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. Neth J Med 2002, 60:216-222.
49. Chitturi S, Le V, Kench J, et al: Gliclazide-induced acute hepatitis with hypersensitivity features. Dig Dis Sci 2002, 47:1107-1110.
50. Lahdenne P, Rapola J, Ylijoki H, et al.: Hepatotoxicity in patients with juvenile idiopathic arthritis receiving long-term methotrexate therapy. J Rheumatol 2002, 29:2442-2445.
51. Findings: Arthritis Drug Ban Urged. Washington Post, March 29, 2002: A8.
52. Fathi NH, Mitros F, Hoffamn J, et al.: Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis. J Rheumatol 2002, 29:2092-2098.
53. Kremmer JM, Genovese MC, Cannon GW, et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. Ann Inern Med 2002, 137:726-733.
54. Sanders S, Harisdangkul V: Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci 2002, 323:190-193.
55. Pfeffer MA, Keech A, Sacks FM, et al.: Safety and tolerability of pravastatin in long-term clinical trials. Circulation 2002, 105:2341-2346.
56. Tolman KG: The liver and lovastatin. Am J Cardiof 2002, 89:1411-1413.
57. Carvajal GP, Garcia D, Sanchaz SA, et al.: Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 2002, 63:135-137.
58. Stewart DE: Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 2002, 47:375-377.
59. Overstreet K, Costanza C, Behling C, et al.: Fatal progressive hepatic necrosis associated with lamotrigine treatment, a case report and literature review. Dig Dis Sci 2002, 47:1921-1925.
60. Fisher A, Croft-Baker J, Davis M, et al.: Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord 2002, 17:1362-1365.
61. Kalapos MP: Carbamazepine-provoked hepatotoxicity and possible aetiopathologic role of glutathione in the events. Retrospective review of old data and call for new investigation. Adverse Drug React Toxicol Rev 2002, 1:123-141.
62. Ramos AM, Gayotto LC, Clemente CM, et al.: Reversible vanishing bile duct syndrome induced by carbamazepine Eur J Gastroenterol Hepatol 2002, 14:1019-1022.
63. Frey B, Braegger CP, Ghelfi D: Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast feeding. Ann Pharmacother 2002, 36:644-647.
64. Teleman MD, Chee CB, Earnest A, et al.: Hepatotoxicity of tuberculosis chemotherapy under a general program conditions in Singapore. Int J Tuberc Lung Dis 2002, 6:699-705.
65. Patel PA, Voigt MD: Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastrotenterol 2002, 97:1198-1203.
66. Sharma SK, Balamurugan A, Saha PK, et al.: Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002, 166:916-919.
67. Huang YS, Chern HD, Su WJ, et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002, 35:883-889. Patients who had a slow acetylator phenotype were at increased risk of toxicity.
68. Ohkawa K, Hashiguchi M, Ohno K: Risk factors for antituberculosis chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther 2002, 72:220-226.
69. Finch CK, Chrisman CR, Baciewcz AM, et al.: Rifampin and rifabutin interactions. Arch Intern Med 2002, 162:985-992.
70. Dourakis S, Papanikolaou, Tzemanakis EN, et al.: Acute hepatitis associated with herb (Teucrium capitatum L.) administration. Eur J Gastroenterol Hepatol 2002, 14:693-695.
71. Stedman C: Herbal hepatotoxicity. Semin Liver Dis 2002, 22:195-206. Excellent review of herbal hepatotoxicity
72. Favreau JT, Ryu ML, Braunstein G, et al.: Severe hepatotoxioity associated with the dietary supplement lipokinetix Ann Intern Med 2002, 136:590-595.
73. Safety Information Summaries [Food and Drug Administration]. Available at: http://www.fda.gov/medwatch/safety/2001/safety01.htm#lipoki. Accessed February 12, 2003.
74. Lewis JD, Strom BL: Balancing safety of dietary supplements with the free market. Ann Intern Med 2002, 136:616-618.
75. Palmon R, Koo BC, Shoultz DA, et al.: Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002, 29:340-345.
76. Sulkowski MS, Thomas DL, Mehta SH, et al.: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: a role of hepatitis C and B infections. Hepatology 2002, 35:182-189. Prospective review of the incidence and risk factors of hepatotoxicity in HIV-positive patients who are taking non-nucleoside reverse transcriptase inhibitors.
77. Bonnet F, Lawson-Ayayi S, Thiebaut R, et al.: A cohort study of nevirapine tolerance in clinical practice: a French Aquitaine cohort, 1997-1999. Clin Infect Dis 2002, 35:1231-1237.
78. Aceti A, Pasquazzi C, Zechini B, et al.: Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquit Immune Defic Syndr 2002, 29:41-48. Chronic hepatitis B and C are important risk factors for increased hepatotoxicity in patients taking protease inhibitors.
79. De Luca A, Bugarini R, Cozzi-Lepri A, et al.: Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects. Arch Intern Med 2002, 162:2125-2132
80. Nunez M, Rios P, Martin-Carbonero L, et al.: Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 30:65-68.
81. Wit FW, Weverling GJ, Weel J: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J infect Dis 2002, 186:23-31.
82. De Matt MM, Mathot RA, Veldkamp AI, et al.: Hepatotoxicity following nevirapine-containing regimens in HIV-1 infected individuals. Pharmacol Res 2002, 46:295-300.
83. Gokengin D, Yamazhan T: Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case report. Ann Clin Antimicrob 2002, 1:1.
84. Orenstein R, Tsongas N: Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection. Pharmacotherapy 2002, 22:1468-1478. The authors remind us of the need to consider other factors and drugs when considering a diagnosis of possible antiretroviral therapy-related hepatotoxicity.
85. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, et al.: Liver toxicity caused by nevirapine. AIDS 2002, 16:290-291.
86. Johnson S, Chan J, Bennett CL: Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen Ann Intern Med 2002, 137:146-147.
87. Bjornsson E, Nordlinder H, Olsson R: Metronidazole as a probable cause of severe liver injury. Hepatogastroenterolgy 2002, 49:252-254.
88. Andrade RJ, Lucena MI, Fernandez MC, et al.: Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. 2002, 14:887-890.
89. Gonzalez GA, Garcia Sanchez MV, La Mata Garcia MD, et al.: Early-onset acute toxic induced by intravenous amiodarone administration. Gastoenterol Hepatol 2002, 25:392-394.
90. Giannasttasio F, Salvio A, Varriale M: Three cases of severe acute hepatitis after parenteral administration of amiodarone: the active ingredient is not the only agent responsible for hepatotoxicity. Ann Ital Med Int 2002, 17:180-184.
91. Al-Homaidhi H, Abdel-Haq NM, El-Baba M, et al.: Severe hepatitis associated with oxacillin therapy. South Med J 2002, 95:650-652.
92. Suriawinata A, Min AD: A 33-year-old woman with jaundice after azithromycin use. Semin Liver Dis 2002, 22:207-210.
93. Chandrupatla S, Demetris AJ, Rabinovitz M: Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci 2002, 47:2186-2188.
94. Kanda T, Yokosuka O, Fujiwara K, et al.: Fulminant hepatic failure associated with triazolam. Dig Dis Sci 2002, 47:1111-1114.
95. Azaz-Livshits T, Hershko A, Ben-Chetrit E: Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature. Pharmacopsychiatry 2002, 35:112-115.
96. Marinella MA: Labetalol-induced hepatitis in a patient with chronic hepatitis B infection. J Clin Hypertens 2002, 4:120-121.
97. Graffin H, Genty I, Cretel E, et al.: Beta-carotene-induced hepatic fibrosis. Dig Dis Sci 2002, 47:793.
98. Sommers LM, Schoene RB: Allopurinol hypersensitivity syndrome associated with pancreatic exocrine abnormalities exocrine abnormalities and new-onset diabetes mellitus. Arch Intern Med 2002, 162:1190-1192.
99. Da Silveira EB, Young K, Rodriguez M, et al.: Reye's syndrome in a 17-year-old male: is the disease really disappearing? Dig Dis Sci 2002, 47:1959-1961.
100. Gupta AK, Chwetzoff E, Del Rosso J, et al.: Hepatic safety of itraconazole. J Cutan Med Surg 2002, 6:210-213.
101. Grieco A, Forgione A, Giorgi A, et al.: Propafenone-related cholestatic hepatitis in an elderly patient. Ital Heart J 2002, 3:431-434.
102. Lange-Brock N, Berg T, Muller AR, et al.: Acute liver failure following the use of ectasy (MDMA). Z Gastroenterol 2002, 40:581-586.
103. Lopez-Torres E, Lucena MI, Andrade RJ, et al.: Tetrabamate-induced hepatotoxicity. Report of seven cases and literature review [in Spanish]. Gastroenterol Hepatol 2002, 25:589-593.
104. Fox JC, Szyjkewkski RS, Sanderson SO: Progressive chelestatic liver disease associated with clarithromycin treatment. J Clin Pharmacol 2002, 42:676-689.
105. Grieco A, Miele L, Giorgi A: Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother 2002, 36:1887-1889.
106. Woeber KA: Methimazole-induced hepatotoxicity. Endocr Pract 2002, 8:222-224.
107. Anania FA, Rabin L: Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med 2002, 112:741-742.
108. Cote HCF, Brumme ZL, Craib KJ, et al.: Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl Med 2002, 346:811-820.
109. Boelsterli UA: Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf 2002, 25:633-648.
110. Masubuchi Y, Nakayama S, Horie T: Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 2002, 35:544-551.
111. Schwab M, Schaffler E, Marx C et al.: Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002, 12:429-436.
112. Lewis JH: The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf 2002, 1:159-172. One author's approach to prescribing potentially hepatotoxic drugs to patients with chronic liver disease. A strategy of close monitoring and clinical vigilance is recommended.
113. Zimmerman HJ: Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999: 430.